ArticleAmerican journal of obstetrics and gynecology2011
Pharmacokinetics of oseltamivir according to trimester of pregnancy.
Article in American journal of obstetrics and gynecology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.British journal of clinical pharmacology · 2015Trial
- Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition).Infectious diseases & immunity · 2026Article
- Viral threats to pregnancy: Global health risks in the era of pandemics.Advances in virus research · 2026Review
- Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy.Open forum infectious diseases · 2021Review
- Use of antiviral drugs for seasonal influenza: Foundation document for practitioners-Update 2019.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2019Article
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- A travelling camper with a spiking fever, headache, myalgia, hepatitis, and intracellular inclusions.The Lancet. Infectious diseases · 2017Article
- Antiviral Treatments.Clinics in chest medicine · 2017Review
- Oseltamivir for influenza in pregnancy.Seminars in perinatology · 2014Review
- Risk management of seasonal influenza during pregnancy: current perspectives.International journal of women's health · 2014Review
- Influenza in pregnancy.Influenza and other respiratory viruses · 2013Review
- Report of the first Asia-Pacific Forum on antiviral treatment of influenza, Asia-Pacific Alliance for the Control of Influenza, Bangkok, 14 June 2012.Influenza and other respiratory viruses · 2013Article
- Clinical use of approved influenza antivirals: therapy and prophylaxis.Influenza and other respiratory viruses · 2013Review
- The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.British journal of clinical pharmacology · 2012Review
- The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2012Article
- We don't know what we don't study: the case for research on medication effects in pregnancy.American journal of medical genetics. Part C, Seminars in medical genetics · 2011Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.